
## 1/13

	•	
HuNAIL	MLGQVVTLILLLLKVYQGKGCQGSADHVVSISGVPLQLQPNSIQTKVDS	
Mu2B4	MLGQAVLFTTFLLLRAHQGQDCPDSSEEVVGVSGKPVQLRPSNIQTKDVS	50
	IAWKKLLPSQNGFHHILKWEN-GSLPSNTS-NDRFSFIVKNLSLLIKAAQ	98
• .	VQWKKTEQGSHRKIEILNWYNDGPSWSNVSFSDIYGFDYGDFALSIKSAK	100
	QQDSGLYCLEVTSISGKVQTATFQVFVFDKVEKPRLQGQGKILDRGRCQV	148
		150
	ALSCLVSRDGNVSYA-WYRGSKLIQTAGNLTYLDEEVDINGTHTYTCNVS	197
		200
	NPVSWESHTLNLTQDCQNAHQEFRFWPFLVIIVILSALFLGTLACFCVWR	247
		250
	RKRKEKQSETSPKEFLTIYEDVKDLKTRRNHE	279
		298
	QEQTFPGGGSTIYSMIQSQSSAPTSQEPAYTLYSL	314
	QRELDRRVSEVLEQLPQQTFPGDRGTMYSMIQCKPSDSTSQEKC-TVYSV	347
•	IQPSRKSGSRKRNHSPSFNSTIYEVIGKSQPKAQNPARLSRKELENFDVY	364
	S	365
	Ĭ	398

## FIG. 1



3/13

U937 CD8+
NK CELLS | PBT | RAJI
9.57.54.42.4
1.35
ACTIN

FIG. 2B

4/13

NAIL CONTROL
TRANSFECTION: NAIL CONTROL

250-

98-

64-


50-

36-


16-

Na PERVANADATE:

FIG. 2C

















FIG. 4A






FIG. 5



specific cytotoxicity (%)

10/13



F/G. 6A

11 / 13




FIG. 6B

12/13

